Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Tennessee
About this trial
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.
Eligibility criteria
Qualifiers
All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
Must be able to schedule and tolerate additional PET/CT imaging following therapy
Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.
Disqualifiers
Patients that are not candidates for Y90 radioembolization therapy
Patients that cannot tolerate additional imaging procedures following therapy
Patients that cannot tolerate the additional blood draws required for this study
Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study
Trial design
Treatments tested in this trial
- Post therapy PET/CT Imaging
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Tennessee
Lead sponsor
Biocompatibles UK Ltd
Collaborator
Source ClinicalTrials.gov